A composition comprising or consisting of L-theanine and one or more fructooligosaccharides, wherein the ratio of L-theanine to froctooligosaccharide(s) is of about 2:1 to 99:1. A composition in the form of a food or nutraceutical, and also in the form of a powder, granules, suspension, tablet, capsule, lozenge, bakery item, sweets, drink, beverage or oral preparation.

A composition comprising or consisting of L-theanine and one or more fructooligosaccharides, wherein the ratio of L-theanine to froctooligosaccharide(s) is of about 2:1 to 99:1. A composition in the form of a food or nutraceutical, and also in the form of a powder, granules, suspension, tablet, capsule, lozenge, bakery item, sweets, drink, beverage or oral preparation.

A composition comprising or consisting of L-theanine and one or more fructooligosaccharides, wherein the ratio of L-theanine to froctooligosaccharide(s) is of about 2:1 to 99:1. A composition in the form of a food or nutraceutical, and also in the form of a powder, granules, suspension, tablet, capsule, lozenge, bakery item, sweets, drink, beverage or oral preparation.

The present disclosure relates to compositions comprising dietary fibers. For example, in some embodiments, the composition comprises two or more fibers (e.g., fibers such as beta-glucan, wheat dextrin, inulin, pectin, psyllium, or potato starch) each present in amount of about 40% to about 60% w/w of the composition. In some embodiments, the composition further includes a sweetener and/or a flavoring agent. Such compositions are useful in the treatment or improvement of gastrointestinal diseases.

The present disclosure relates to compositions comprising dietary fibers. For example, in some embodiments, the composition comprises two or more fibers (e.g., fibers such as beta-glucan, wheat dextrin, inulin, pectin, psyllium, or potato starch) each present in amount of about 40% to about 60% w/w of the composition. In some embodiments, the composition further includes a sweetener and/or a flavoring agent. Such compositions are useful in the treatment or improvement of gastrointestinal diseases.

There is provided a composition that comprises a propionic acid bacterium or a composition that comprises an oligosaccharide. The composition that comprises a propionic acid bacterium or the composition that comprises an oligosaccharide can suppress an increase of body weight of a subject by having the subject ingest the composition.

There is provided a composition that comprises a propionic acid bacterium or a composition that comprises an oligosaccharide. The composition that comprises a propionic acid bacterium or the composition that comprises an oligosaccharide can suppress an increase of body weight of a subject by having the subject ingest the composition.

A method of treating a symptom of neurodegenerative disease in a mammal subject includes administering a ganglioside preparation enriched in GM1, derived from an ovine animal afflicted with GM1 gangliosidosis. The ganglioside preparation is prepared through tissue isolation, extraction, and purification processes. The method includes the treatment of a symptom of Huntington's disease and other neurodegenerative diseases. A selective breeding method for producing a GM1 gangliosidosis-affected, scrapie-resistant ovine animal that produces substantially high tissue concentrations of GM1 ganglioside is described. A method to produce multiple successive generations of ovine animals to produce a GM1 gangliosidosis-affected, scrapie-resistant ovine animal and the production of additional generations to improve trait characteristics. The ganglioside product enriched in GM1 is extracted from an ovine animal that is GM1 affected and scrapie-resistant.

A method of treating a symptom of neurodegenerative disease in a mammal subject includes administering a ganglioside preparation enriched in GM1, derived from an ovine animal afflicted with GM1 gangliosidosis. The ganglioside preparation is prepared through tissue isolation, extraction, and purification processes. The method includes the treatment of a symptom of Huntington's disease and other neurodegenerative diseases. A selective breeding method for producing a GM1 gangliosidosis-affected, scrapie-resistant ovine animal that produces substantially high tissue concentrations of GM1 ganglioside is described. A method to produce multiple successive generations of ovine animals to produce a GM1 gangliosidosis-affected, scrapie-resistant ovine animal and the production of additional generations to improve trait characteristics. The ganglioside product enriched in GM1 is extracted from an ovine animal that is GM1 affected and scrapie-resistant.

The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non-intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2′-FL, LNnT, LNT, DFL, and 6′-SL.